National Match Code: 635260
Duration/Type: 12-month residency
Number of Positions: 4
Application Deadline: Dec. 31, 2021
Starting Date: June 2022
The purpose of this PGY2 pharmacy residency program is to build on Doctor of Pharmacy (PharmD) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care or other advanced practice settings. Residents who successfully complete an accredited PGY2 pharmacy residency are prepared for advanced patient care, academic, or other specialized positions, along with board certification, if available.
This specialty residency is designed to provide advanced clinical training in oncology and leadership development opportunities. Upon completion of the residency, the graduates’ advanced knowledge and leadership skills will enable them to practice as an integral member of an interdisciplinary team in the care of the oncology patient, engage in clinical instructor/precepting opportunities and they will be prepared to attain board certification (BCOP).
Flexible, comprehensive training in both acute care and ambulatory oncology settings with a focus on multidisciplinary collaboration.
- Rotations and activities are tailored to meet the needs and interests of each resident.
- Year-long research projects are expected to be submitted for publication.
- Residents will have the opportunity to precept PGY1 pharmacy residents and PharmD students on clinical rotations.
Requirements for Acceptance
- Completion of PGY1 pharmacy residency
- Applicants are required to submit a program application through PhORCAS. Please follow the application instructions.
- Inpatient Rotations (3-4 week rotations in acute care settings, total of ~12 weeks)
- Inpatient Acute Care Oncology
- Inpatient Hematologic Malignancies
- Inpatient Blood and Marrow Transplant
- Ambulatory Oncology (2-week rotations in disease state clinics, total of ~10 weeks)
- Ambulatory Hematology/Blood and Marrow transplant
- Ambulatory GI Clinic
- Ambulatory Gyn/Onc and Thoracic Clinic
- Ambulatory Breast Clinic
- Ambulatory Genitourinary and Sarcoma Clinic
- Ambulatory Central Nervous System, Head and Neck, Skin and Endocrine Clinic
- Investigational Drug Service (scope: clinical, operational, and administrative)
- Longitudinal Quarter-Rotated Experiences (3 months each)
- Drug Policy (concurrent with Oncology Pharmacy & Therapeutics Subcommittee)
- Multidisciplinary Collaboration (concurrent with Oncology Pharmacy & Nursing Committee and Molecular Tumor Board)
- Pharmacogenomics (concurrent with Molecular Tumor Board)
- Medication Safety and Leadership (Medication Error Review and Reporting)
- Longitudinal Research Project (12 months)
- Longitudinal Didactic Discussion (12 months)
- Advanced Clinical Practice Oncology
- Academia Oncology
- Critical Care Oncology
- Informatics Oncology
- Infectious Disease - Immunocompromised Care
- Pediatric Oncology (Children’s Wisconsin)
Requirements and Expectations
In addition to requirements for individual learning experiences, satisfactory completion of the below list is required to earn a Froedtert Hospital PGY2 Oncology Residency certificate. Pharmacy residents are required to be licensed in the state of Wisconsin within 90 days of start date with the Froedtert & MCW health network.
Clinical and Operations Practice (On-Site Staffing) Requirements
- Includes 20 weekend shifts (10 weekends), 7 staffing weeks (Mon-Fri), 2 holiday shifts, and up to 4 additional weekday shifts.
- Weekends are prioritized to be staffed in oncology areas, however, residents may take non-oncology shifts as available in cross-trained areas
- Residents may also be required to staff up to four additional ten-hour shifts distributed throughout the year without bonus pay.
- Resident staffing beyond the above requirements are eligible for bonus pay (see section on bonus shifts)
Investigational Drug Service (IDS) Call for PGY2 Oncology Residents
- Residents are expected to take call during on-site staffing weekends and holidays in addition to filling gap weekends in IDS Pharmacist call schedule (approximately one weekend per month).
Student Precepting Opportunities
- May serve as primary preceptor for IPPE students, based on scheduled learning experiences
- Assist with precepting responsibilities for APPE students during learning experiences, including longitudinal
- Assist with precepting PGY-1 residents completing oncology based learning experiences
Committee Opportunities and Responsibility
- Longitudinal responsibilities: Attend and complete small projects, prepare and take minutes for each of the following committees during related longitudinal learning experiences
- Froedtert Oncology Pharmacy & Therapeutics Subcommittee (OP&T)
- Froedtert Oncology Pharmacy & Nursing Committee (OPNC)
- Froedtert Molecular Tumor Board (MTB)
- Optional Opportunities
- Vizient Pharmacy Cancer Care Committee
Department Meeting Attendance
Residents are expected to be present at the meetings below that occur during learning experience time. It is acceptable to miss a meeting if patient care demands warrant; however, the situation should be communicated to the residency program director or coordinator. During clinical staffing, meeting attendance is not required. If the workload permits, residents may attend meetings at the discretion of their staffing preceptor. The resident should not schedule additional meetings during staffing shifts (ie. mentor meetings, project team meetings, etc).
- Weekly Oncology Residency Discussions
- Weekly Hematology & Oncology Fellow’s Core Education
- Weekly Resident Academic Half-Day Discussions – optional based on topic and past participation (internal PGY2s)
- Monthly Pharmacy Grand Rounds
- Monthly Oncology Pharmacy Grand Rounds
- Monthly Inpatient Staff Meetings
- Monthly Oncology Staff Meetings
Professional Organization Membership
Professional organizations offer residents additional resources and education opportunities as well as access to networking outside of Froedtert & MCW health network. Residents are highly encouraged to engage in active membership in at least one professional organization during residency and to continue to build upon membership into their careers.
- Hematology & Oncology Pharmacy Association (HOPA)
- American Society of Blood & Marrow Transplant (ASBMT) Pharmacy SIG
- American Society of Health-System Pharmacists (ASHP)
- Pharmacy Society of Wisconsin (PSW)
- American College of Clinical Pharmacy (ACCP)
Professional Conference Attendance
- HOPA Annual Meeting
- Greater Milwaukee College of Clinical Pharmacy (GMCCP) Resident Research Symposium
- Vizient Clinical Meeting (required if attending ASHP Midyear Clinical Meeting)
- ASHP Midyear Clinical Meeting
- Milwaukee Residency Conferences
- BMT Tandem Annual meeting
- Pharmacy Society of Wisconsin (PSW) Annual Meeting or Educational Conference
- HOPA Practice Management Meeting
- Major Project Poster Presentations
- Vizient Clinical Meeting (if attending ASHP Midyear Clinical Meeting)
- HOPA Annual Meeting
- Two Froedtert & MCW Oncology Grand Rounds (with continuing education for pharmacists) - each presented twice for A/B weeks
- Resident Research Project Close Out Presentation to Staff
- Major Project Poster Presentations
- HOPA National Journal Club Presentation
- Oncology care support group meeting
- Froedtert/Aurora Local Networking Journal Club
Resident Research Project
Residents will choose a longitudinal research project at the beginning of the year, and will form a project team. Residents are required to complete the following throughout the year:
- CITI / GCP Training
- Pharmacy Research Committee Protocol Approval
- IRB submission (if applicable)
- UHC December Council meeting – Abstract and Poster
- HOPA Annual Meeting –Abstract and Poster
- Resident research project must be summarized in a written format acceptable for publication. Residents are expected to pursue publication and/or presentation of their project in a peer-review setting.
- MCW program is considered the primary teaching certificate program.
- Residents in PGY1 level programs interested in a teaching certificate will complete their teaching certificate through MCW
- Teaching certificates for PGY2 level programs, as well as other academia opportunities may be pursued through CUW at discretion of program director
- Residents can do an elective academia rotation at either CUW or MCW
- MCW & CUW offer both block academia rotations and longitudinal academic rotations
- PGY2 Oncology Residents are required to participate in two oncology-focused student labs with MCW School of Pharmacy
- PGY2 Residents have an active role in recruitment for incoming PGY2 Oncology pharmacy residency class
- Responsibilities vary based on availability and scheduling, may include:
- ASHP Personnel Placement Service Interviews
- Networking events with candidates (i.e. ASHP residency showcase)
- Developing interview schedules, questions, logistics
- Coordinating, transitioning, directing on interview days
- Candidate lunch and tours for interview days
- Residency mentors are pharmacists assigned to each resident. Their primary purpose is to provide residents guidance throughout the year with an emphasis on self-assessment growth, review and provide feedback on major projects, monitor progress with residency expectations, and facilitate communication between rotations
- Residents and mentors are expected to meet approximately monthly
- Residency advisors are pharmacists assigned to each resident. Their primary purpose is to provide guidance throughout the year with an emphasis on overall professional development and career advancement.
- Residents and advisors are expected to meet approximately monthly
|2020 – 2021||Kate Berlin, PharmD||Malignant Hematology/BMT Clinical Pharmacy Specialist, Northwestern Medicine/Northwestern Memorial Hospital, Chicago, Ill.|
|Jane McCullough, PharmD||Clinical Oncology Pharmacist, Northwestern Medicine/Northwestern Memorial Hospital, Chicago, Ill.|
|Bradley Mayer, PharmD||Clinical Oncology Pharmacist, Froedtert & the Medical College of Wisconsin, Milwaukee, Wis.|
|Michael Robles, PharmD||General Oncology Pharmacist, University of Washington Medicine/Seattle Cancer Care Alliance Seattle, Wash.|
|2019 – 2020||Briana Amundson, PharmD||Clinical Oncology Pharmacist, Froedtert & the Medical College of Wisconsin, Milwaukee, Wis.|
|Jessica McKernan, PharmD||Solid Tumor Clinical Coordinator Pharmacist in CNS/GU Clinic, Atrium Health / Carolinas Medical Center, Charlotte, N.C.|
|Maggie Nelson, PharmD||Clinical Oncology Pharmacist for Bone and Marrow Transplant, University of Kansas HealthSystem, Kansas City, Kan.|
|Julia Stevens, PharmD||Clinical Oncology Pharmacist, Beth Israel Deaconess Medical Center, Boston, Mass.|
|2018 – 2019||Monica Chintapenta, PharmD, BCOP||Clinical Specialist I - Oncology, Houston Methodist Hospital, Houston, Tex.|
|Sara Harstad, PharmD, BCOP||Inpatient Clinical Oncology Pharmacist- Pediatric and Adult Populations, Wilmot Cancer Institute - University of Rochester Medical Center Rochester, N.Y.|
|Melika Fini, PharmD, BCOP||Clinical Oncology Staff Pharmacist, Rush University Medical Center, Chicago, Ill.|
|Katelyn Patterson, PharmD||Ambulatory Hematology and Oncology Pharmacist, Henry Ford Hospital - Henry Ford Health System Detroit, Mich.|
|2017 – 2018||Stephanie Spitzer (Free), PharmD||Clinical Oncology Pharmacist, Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wis.|
|Cole Lightfoot, PharmD, BCOP||Clinical Oncology Pharmacist, Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wis.|
|Erin McGurty, PharmD, BCOP||Clinical Oncology Pharmacist, Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wis.|
|2016 – 2017||Allison Martin, PharmD, BCOP||BMT Pharmacist Clinical Coordinator, Levine Cancer Institute of Carolinas HealthCare System Charlotte, NC|
|Thomas Nowak, PharmD||Clinical Oncology Pharmacist, Drexel Town Square, Froedtert Hospital & the Medical College of Wisconsin, Oak Creek, Wis.|
|Puja Patel, PharmD, BCOP||Assistant Professor, Marshall B. Ketchum University – College of Pharmacy, Fullerton, Cal.|
|2015 – 2016||Nicole Zimmerman (Gunderson), PharmD||Clinical Oncology Pharmacist, ThedaCare Regional Cancer Center, Appleton, Wis.|
|Rachel Emerton (Pritchett), PharmD, BCOP||Clinical Oncology Pharmacist, Columbus Regional Health, Columbus, Ind.|
|2014 – 2015||Aaron Lorge, PharmD, BCOP||Clinical Oncology Pharmacist, Froedtert Hospital & the Medical College of Wisconsin, Milwaukee Wis.|
|Elizabeth Weil, PharmD, BCOP||Clinical Oncology Pharmacist, Froedtert Hospital & the Medical College of Wisconsin, Milwaukee Wis.|
|2013 – 2014||Danielle Gundrum (Maila), PharmD, BCOP||Pharmacy Practice Faculty – Oncology, Roseman University of Health Sciences School of Pharmacy, South Jordan, Ut.
Oncology Pharmacist, Intermountain Medical Center, Murray, Ut.
|Elizabeth Dow-Hillgartner, PharmD, BCPS, BCOP||Clinical Pharmacy Specialist in Hematology/Oncology, University Hospital; UW Health, Madison, Wis.|
|2012 – 2013||Melissa Rhoades (Handcock), PharmD, BCOP||Clinical Oncology Pharmacist Coordinator, PGY2 Oncology Residency Program Director, Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wis.|
|2011 – 2012||Felicia Zook (Falvo), PharmD, BCOP||Clinical Oncology Pharmacist, PGY2 Oncology Residency Program Coordinator, Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wis.|
|2010 – 2011||Janelle Mann, PharmD, BCOP||Clinical Oncology Pharmacist, Investigational Drug Services, Washington University Infusion Center Pharmacy
Adjunct Assistant Professor, Department of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Mo.